UM
CORT icon

UniSuper Management’s Corcept Therapeutics CORT Stock Holding History

UniSuper Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,536
Closed -$570K – 767
2024
Q2 		$570K Hold
17,536
– – ﹤0.01% 736
2024
Q1 		$442K Buy
+17,536
New +$414K ﹤0.01% 787

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

UniSuper Management's CORT Position: Q3 2024 in Review

UniSuper Management sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 17,536 shares — an estimated $570K sold.

UniSuper Management first reported a position in CORT in Q1 2024 and held it in 2 quarters. The position peaked at $570K in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • UniSuper Management reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • UniSuper Management sold 17,536 Corcept Therapeutics shares in Q3 2024, an estimated $570K.
  • UniSuper Management first reported a position in Corcept Therapeutics in Q1 2024 and held it in 2 quarters.
  • UniSuper Management's Corcept Therapeutics position peaked at $570K in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on UniSuper Management's 13F filing for Q3 2024, filed 14 Nov 2024.